JP6824502B2 - オキサスピロ誘導体、その製造方法、及び医薬におけるその適用 - Google Patents
オキサスピロ誘導体、その製造方法、及び医薬におけるその適用 Download PDFInfo
- Publication number
- JP6824502B2 JP6824502B2 JP2018515975A JP2018515975A JP6824502B2 JP 6824502 B2 JP6824502 B2 JP 6824502B2 JP 2018515975 A JP2018515975 A JP 2018515975A JP 2018515975 A JP2018515975 A JP 2018515975A JP 6824502 B2 JP6824502 B2 JP 6824502B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- compound
- heterocyclyl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510665328.X | 2015-10-15 | ||
| CN201510665328 | 2015-10-15 | ||
| CN201511032876 | 2015-12-31 | ||
| CN201511032876.5 | 2015-12-31 | ||
| PCT/CN2016/101064 WO2017063509A1 (zh) | 2015-10-15 | 2016-09-30 | 氧杂螺环类衍生物、其制备方法及其在医药上的应用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018534257A JP2018534257A (ja) | 2018-11-22 |
| JP2018534257A5 JP2018534257A5 (enExample) | 2019-10-10 |
| JP6824502B2 true JP6824502B2 (ja) | 2021-02-03 |
Family
ID=58517778
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018515975A Active JP6824502B2 (ja) | 2015-10-15 | 2016-09-30 | オキサスピロ誘導体、その製造方法、及び医薬におけるその適用 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10442793B2 (enExample) |
| EP (1) | EP3354649B1 (enExample) |
| JP (1) | JP6824502B2 (enExample) |
| KR (1) | KR102703513B1 (enExample) |
| CN (1) | CN107001347B (enExample) |
| AU (1) | AU2016339404B2 (enExample) |
| CA (1) | CA3000761C (enExample) |
| DK (1) | DK3354649T3 (enExample) |
| ES (1) | ES2772689T3 (enExample) |
| HU (1) | HUE048032T2 (enExample) |
| MX (1) | MX382815B (enExample) |
| PL (1) | PL3354649T3 (enExample) |
| PT (1) | PT3354649T (enExample) |
| RU (1) | RU2733373C2 (enExample) |
| TW (1) | TWI727981B (enExample) |
| WO (1) | WO2017063509A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020516642A (ja) * | 2017-04-14 | 2020-06-11 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． | オピオイド受容体（ｍｏｒ）アゴニスト塩、そのフマレート塩ｉ結晶形態、およびその製造方法 |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX388643B (es) * | 2017-04-14 | 2025-03-20 | Jiangsu Hengrui Medicine Co | Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos |
| CN108727347B (zh) * | 2017-04-14 | 2020-06-16 | 江苏恒瑞医药股份有限公司 | 一种阿片样物质受体(mor)激动剂的晶型及其制备方法 |
| CN109206417B (zh) * | 2017-07-04 | 2023-01-03 | 四川海思科制药有限公司 | 阿片受体激动剂及其应用 |
| US11072601B2 (en) | 2017-09-18 | 2021-07-27 | Shanghai Synergy Pharmaceutical Sciences Co., Ltd. | μ-opioid receptor agonist and preparation method therefor and use thereof in field of medicine |
| WO2019062804A1 (zh) | 2017-09-28 | 2019-04-04 | 江苏恒瑞医药股份有限公司 | 一种氧杂螺环类衍生物的制备方法及其中间体 |
| AU2018349930A1 (en) * | 2017-10-13 | 2020-04-16 | Shandong Luye Pharmaceutical Co., Ltd. | 2,6-dioxaspiro (4,5) decane derivatives and preparation method therefor and pharmaceutical applications thereof |
| JP2021505547A (ja) * | 2017-12-06 | 2021-02-18 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 疼痛を治療するための薬物の製造におけるｍｏｒアゴニストと組み合わせたｋｏｒアゴニストの使用 |
| CN111836807A (zh) * | 2018-04-28 | 2020-10-27 | 四川科伦博泰生物医药股份有限公司 | 氧杂螺环类化合物及其制备方法和用途 |
| CN108424372B (zh) * | 2018-05-11 | 2021-08-10 | 浙江华贝药业有限责任公司 | 2，2，2-三氟-n-[(s)-4-羰基四氢萘-1-基]-乙酰胺的纯化工艺 |
| CN111163778B (zh) * | 2018-05-14 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | 一种mor受体激动剂药物组合物 |
| CN108707086B (zh) * | 2018-05-15 | 2021-08-10 | 浙江华贝药业有限责任公司 | 一种(1s，4s)-n-（4-羟基四氢萘-1-基）叔丁氧基碳酰胺的纯化工艺 |
| WO2020073985A1 (zh) * | 2018-10-12 | 2020-04-16 | 江苏恒瑞医药股份有限公司 | 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 |
| WO2020073984A1 (zh) * | 2018-10-12 | 2020-04-16 | 江苏恒瑞医药股份有限公司 | 一种阿片样物质受体(mor)激动剂的结晶形式及制备方法 |
| CN112334465B (zh) * | 2019-01-17 | 2024-06-11 | 上海海雁医药科技有限公司 | 三环取代的氧杂螺环衍生物、其制法与医药上的用途 |
| CN111662284B (zh) * | 2019-03-06 | 2021-08-10 | 上海海雁医药科技有限公司 | 双杂环取代的氧杂螺环衍生物、其制法与医药上的用途 |
| WO2021027304A1 (zh) * | 2019-08-14 | 2021-02-18 | 上海海雁医药科技有限公司 | 镇痛化合物、其制法与医药上的用途 |
| EP4092031A4 (en) * | 2020-01-17 | 2024-02-21 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | AZABICYCLIC SUBSTITUTED OXASPIRO DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND ITS MEDICAL USE |
| CN118221680A (zh) | 2020-01-17 | 2024-06-21 | 上海海雁医药科技有限公司 | 光学纯的氧杂螺环取代的吡咯并吡唑衍生物、其制法与医药上的用途 |
| CN113214264B (zh) * | 2020-01-21 | 2022-08-09 | 上海海雁医药科技有限公司 | 二氢吡咯并五元杂芳基取代的氧杂螺环衍生物、其制法与医药上的用途 |
| JP7781064B2 (ja) | 2020-01-22 | 2025-12-05 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 抗ｔｒｏｐ－２抗体－エキサテカン類似体複合体及びその医薬用途 |
| CN114075141B (zh) * | 2020-08-20 | 2025-02-25 | 上海致根医药科技有限公司 | 阿片受体“偏向性”配体、其制备方法及其在医药上的应用 |
| CN114539257B (zh) * | 2020-11-24 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用 |
| JP7751645B2 (ja) | 2020-12-29 | 2025-10-08 | 上海海雁医薬科技有限公司 | オキシスピロ環置換ピロロピラゾール誘導体及びその中間体並びにその調製方法 |
| WO2023284788A1 (zh) | 2021-07-13 | 2023-01-19 | 上海海雁医药科技有限公司 | Mor受体激动剂的药学上可接受的盐、其多晶型物及其用途 |
| WO2023011422A1 (zh) * | 2021-08-02 | 2023-02-09 | 上海枢境生物科技有限公司 | 氧杂螺环类衍生物、制备方法及其用途 |
| CN117263956A (zh) * | 2022-01-19 | 2023-12-22 | 天地恒一制药股份有限公司 | 阿片受体激动剂及其制备方法和用途 |
| CN116589451B (zh) * | 2022-02-11 | 2024-07-09 | 成都硕德药业有限公司 | 一种6-氧杂螺[4,5]癸烷类化合物的新晶型、用途及其制备方法 |
| CN117624138A (zh) * | 2022-08-29 | 2024-03-01 | 江苏恒瑞医药股份有限公司 | 一种氧杂螺环类衍生物的可药用盐、晶型及制备方法 |
| CN119894904B (zh) * | 2022-09-27 | 2025-12-30 | 上海枢境生物科技有限公司 | 一种含螺环类衍生物的盐、晶型及其制备方法和应用 |
| KR20250137614A (ko) | 2023-01-18 | 2025-09-18 | 상하이 센후이 메디슨 컴퍼니 리미티드 | 테트라히드로-1-나프틸아민 및 이의 유도체의 제조 방법 |
| WO2026026772A1 (zh) * | 2024-07-30 | 2026-02-05 | 上海枢境生物科技有限公司 | 氧杂螺环类衍生物的富马酸盐晶型及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2160534B1 (es) | 1999-12-30 | 2002-04-16 | Vita Invest Sa | Nuevos esteres derivados de (rr,ss)-2-hidroxibenzoato de 3-(2-dimetilaminometil-1-hidroxiciclohexil) fenilo. |
| DE10044649A1 (de) | 2000-09-08 | 2002-07-04 | Gruenenthal Gmbh | Substituierte 4-Phenyl-1-(1-phenyl-cyclohexyl)-1,2,3,6-tetrahydropyridine |
| DE102006033109A1 (de) * | 2006-07-18 | 2008-01-31 | Grünenthal GmbH | Substituierte Heteroaryl-Derivate |
| US7999107B2 (en) * | 2007-01-31 | 2011-08-16 | Merck Sharp & Dohme Corp. | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators |
| US20090028873A1 (en) | 2007-07-27 | 2009-01-29 | Auspex Pharmaceuticals, Inc. | Substituted cyclohexanols |
| AU2009308769B2 (en) | 2008-10-31 | 2015-03-12 | Pain Therapeutics, Inc. | Filamin A-binding anti-inflammatory analgesic |
| CN102741258B (zh) | 2009-06-17 | 2015-09-30 | 德州大学体系董事会 | 作为分离剂的环果聚糖的组成物及方法 |
| SI2688403T1 (sl) * | 2011-03-23 | 2017-08-31 | Trevena, Inc. | Ligandi opioidnih receptorjev in metode uporabe in izdelave istega |
| CN104159902B (zh) | 2011-12-12 | 2016-05-04 | 格吕伦塔尔有限公司 | 制备(1r,4r)-6’-氟-(N,N-二甲基-和N-甲基)-4-苯基-4’,9’-二氢-3’H-螺[环己烷-1,1’-吡喃并[3,4,b]吲哚]-4-胺的方法 |
| PL2880037T3 (pl) | 2012-08-03 | 2019-07-31 | Johnson Matthey Public Limited Company | Sposób wytwarzania oksykodonu |
| RS55593B1 (sr) | 2012-11-13 | 2017-06-30 | Array Biopharma Inc | Jedinjenja biciklične uree, tiouree, guanidina i cijanoguanidina korisna za lečenje bola |
-
2016
- 2016-09-30 WO PCT/CN2016/101064 patent/WO2017063509A1/zh not_active Ceased
- 2016-09-30 AU AU2016339404A patent/AU2016339404B2/en active Active
- 2016-09-30 DK DK16854888.1T patent/DK3354649T3/da active
- 2016-09-30 CA CA3000761A patent/CA3000761C/en active Active
- 2016-09-30 EP EP16854888.1A patent/EP3354649B1/en active Active
- 2016-09-30 JP JP2018515975A patent/JP6824502B2/ja active Active
- 2016-09-30 ES ES16854888T patent/ES2772689T3/es active Active
- 2016-09-30 HU HUE16854888A patent/HUE048032T2/hu unknown
- 2016-09-30 MX MX2018004175A patent/MX382815B/es unknown
- 2016-09-30 RU RU2018115569A patent/RU2733373C2/ru active
- 2016-09-30 PT PT168548881T patent/PT3354649T/pt unknown
- 2016-09-30 KR KR1020187012600A patent/KR102703513B1/ko active Active
- 2016-09-30 PL PL16854888T patent/PL3354649T3/pl unknown
- 2016-09-30 CN CN201680003945.6A patent/CN107001347B/zh active Active
- 2016-09-30 US US15/766,985 patent/US10442793B2/en active Active
- 2016-10-14 TW TW105133229A patent/TWI727981B/zh active
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020516642A (ja) * | 2017-04-14 | 2020-06-11 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． | オピオイド受容体（ｍｏｒ）アゴニスト塩、そのフマレート塩ｉ結晶形態、およびその製造方法 |
| JP7153030B2 (ja) | 2017-04-14 | 2022-10-13 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | オピオイド受容体（ｍｏｒ）アゴニスト塩、そのフマレート塩ｉ結晶形態、およびその製造方法 |
| JP7153030B6 (ja) | 2017-04-14 | 2023-07-24 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | オピオイド受容体（ｍｏｒ）アゴニスト塩、そのフマレート塩ｉ結晶形態、およびその製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI727981B (zh) | 2021-05-21 |
| CN107001347B (zh) | 2019-09-24 |
| RU2018115569A (ru) | 2019-11-18 |
| HUE048032T2 (hu) | 2020-05-28 |
| AU2016339404A1 (en) | 2018-05-24 |
| US10442793B2 (en) | 2019-10-15 |
| TW201718558A (zh) | 2017-06-01 |
| CA3000761C (en) | 2024-02-13 |
| AU2016339404B2 (en) | 2020-08-27 |
| DK3354649T3 (da) | 2020-02-24 |
| US20180297988A1 (en) | 2018-10-18 |
| RU2018115569A3 (enExample) | 2020-01-20 |
| WO2017063509A1 (zh) | 2017-04-20 |
| KR102703513B1 (ko) | 2024-09-06 |
| CA3000761A1 (en) | 2017-04-20 |
| MX382815B (es) | 2025-03-12 |
| EP3354649B1 (en) | 2019-12-04 |
| RU2733373C2 (ru) | 2020-10-01 |
| EP3354649A1 (en) | 2018-08-01 |
| BR112018006448A2 (pt) | 2018-10-16 |
| JP2018534257A (ja) | 2018-11-22 |
| PT3354649T (pt) | 2020-02-03 |
| EP3354649A4 (en) | 2018-08-08 |
| ES2772689T3 (es) | 2020-07-08 |
| PL3354649T3 (pl) | 2020-07-27 |
| CN107001347A (zh) | 2017-08-01 |
| MX2018004175A (es) | 2018-06-06 |
| KR20180063251A (ko) | 2018-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6824502B2 (ja) | オキサスピロ誘導体、その製造方法、及び医薬におけるその適用 | |
| AU2014369834B2 (en) | Cortistatin analogues and syntheses and uses thereof | |
| JP5564036B2 (ja) | ヒストン脱アセチル化酵素阻害薬としてのスピロ環誘導体 | |
| EP3227271B1 (en) | Heterocyclic derivatives and use thereof | |
| RS55961B1 (sr) | Jedinjenja i njihova upotreba kao bace inhibitori | |
| TWI882060B (zh) | 三環四氫異喹啉類衍生物、其製備方法及其在醫藥上的應用 | |
| JP2007506776A (ja) | ムスカリン受容体のモジュレーターとしてのフェニル−ピペラジン誘導体 | |
| KR20170007481A (ko) | Cxcr2 억제제로서의 1-(시클로펜트-2-엔-1-일)-3-(2-히드록시-3-(아릴술포닐)페닐)우레아 유도체 | |
| CN111499614A (zh) | 四氢异喹啉类衍生物、其制备方法及其在医药上的应用 | |
| TWI858082B (zh) | 吲唑類衍生物、其製備方法及其在醫藥上的應用 | |
| RU2830109C1 (ru) | Трициклическое тетрагидроизохинолиновое производное, способ его получения и его применение в медицине | |
| BR112018006448B1 (pt) | Derivado de oxaespiro, seu uso e processo de preparação, e composição farmacêutica | |
| HK1238242B (zh) | 氧杂螺环类衍生物、其制备方法及其在医药上的应用 | |
| HK40076301A (en) | Tricyclic tetrahydroisoquinoline derivative, preparation method therefor and application thereof in medicine | |
| HK1238242A1 (en) | Oxa spiro derivative, preparation method therefor, and applications thereof in medicines | |
| HK40076301B (zh) | 三环四氢异喹啉类衍生物、其制备方法及其在医药上的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190830 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190830 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200709 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200814 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200924 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20201214 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20201218 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6824502 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |